Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

RSKD March 4, 2026

Riskified Q4 2025 Earnings Call - First GAAP-profitable quarter, record revenue and a shift to gross profit-led growth

Riskified closed Q4 2025 with record quarterly revenue near $100 million and its first-ever GAAP profitable quarter, underscoring improving unit economics even as top-line growth remains modest. Manag...

  • Record Q4 revenue of $99.3 million, and full-year 2025 revenue of $344.6 million, up 6% and 5% year-over-year respectively.
  • Q4 non-GAAP gross profit was $57.3 million, up 16% year-over-year; full-year non-GAAP gross profit was $180.3 million, up 4% year-over-year.
  • Company reported its first-ever GAAP profitable quarter with Q4 net profit of $5.8 million, versus a -$4.1 million loss in prior-year Q4.
  • +17 more takeaways
STVN March 4, 2026

Stevanato Group Q4 2025 Earnings Call - GLP-1s and High-Value Solutions Drive Margin Expansion as Engineering Lags

Stevanato closed fiscal 2025 with a clear bifurcation. The Biopharmaceutical and Diagnostic Solutions business accelerated, led by GLP-1 demand and other high-value offerings, pushing gross margins hi...

  • Fiscal 2025 total company revenue rose 9% at constant currency and 7% on a reported basis versus 2024.
  • Biopharmaceutical and Diagnostic Solutions (BDS) delivered double-digit growth in 2025, offsetting an expected decline in engineering.
  • High-Value Solutions grew 29% in fiscal 2025 and represented about 46% of full-year company revenue.
  • +12 more takeaways
EYE March 4, 2026

National Vision Q4 FY2025 Earnings Call - Transformation drove margin expansion as premium mix and managed-care growth reshape the business

National Vision closed fiscal 2025 with clear proof that its multi-year transformation is working: revenue of $1.99 billion, adjusted comparable store sales +6% for the year, and adjusted operating in...

  • Fiscal 2025 results show tangible progress: net revenue $1.99 billion, adjusted comparable store sales +6%, adjusted operating income $102.5 million, AOI margin 5.2%, and adjusted EPS $0.80 versus $0.52 in 2024.
  • Q4 highlights: net revenue $503 million (+15.1% y/y, includes 53rd week impact elsewhere), adjusted comps +4.8%, adjusted operating income $17.6 million and adjusted EPS $0.15 versus a loss of $0.04 last year.
  • The 53rd week boosted results materially: week 53 represented $35.6 million of net revenue and $3.5 million of adjusted operating income. Comparable metrics are reported on a 52-week basis.
  • +13 more takeaways
VBNK March 4, 2026

VersaBank Q1 2026 Earnings Call - US SRP Momentum Targets CAD 1B Fundings, Driving Record Assets and Operating Leverage

VersaBank opened fiscal 2026 with punch, driven by an accelerating U.S. Structured Receivable Program that produced over CAD 200 million of fundings in Q1 and lifted credit assets and revenue to recor...

  • U.S. Structured Receivable Program (SRP) drove the quarter, with more than CAD 200 million of additional fundings in Q1 and management targeting at least CAD 1 billion of new fundings in fiscal 2026.
  • Credit assets reached a record CAD 5.33 billion at quarter end, with the SRP portfolio at CAD 4.4 billion, representing 83% of total credit assets.
  • Total consolidated revenue hit a record CAD 36.5 million, up 31% year-over-year and 4% sequentially, reflecting SRP momentum and asset growth.
  • +12 more takeaways
EYPT March 4, 2026

EyePoint Pharmaceuticals Fourth Quarter 2025 Earnings Call - DURAVYU on track for mid-2026 wet AMD top-line; cash runway to Q4 2027

EyePoint closed 2025 with clear focus and deliberate execution, centering the company on DURAVYU as a potential durable blockbuster for wet AMD and DME. Management reports both LUGANO and LUCIA Phase ...

  • DURAVYU Phase 3 wet AMD program (LUGANO and LUCIA) is progressing, with top-line results expected beginning mid-2026.
  • First patients dosed in two pivotal Phase 3 DME trials, COMO and CAPRI; topline DME data expected in the second half of 2027.
  • EyePoint reports a favorable cumulative safety profile across ~191 patients: no ocular or systemic SAEs attributed to DURAVYU and no reported uveitis or vitritis.
  • +13 more takeaways
HLLY March 4, 2026

Holley Performance Brands Q4 & FY 2025 Earnings Call - Core Growth Every Quarter, >20% Adjusted EBITDA and Leverage <3.8x

Holley closed 2025 with a disciplined reset that finally shows up in the numbers. For the first time since 2021 the company delivered full-year reported net sales growth while pushing adjusted EBITDA ...

  • Holley delivered full-year net sales of $613.5 million in 2025, the first annual top-line growth since 2021, with core net sales up ~6.6% for the year.
  • The company achieved adjusted EBITDA of $124.0 million for FY2025, driving adjusted EBITDA margin above 20% (20.2%) for the first time since 2021.
  • Core business grew in every quarter of 2025, accelerating to 13.5% core growth in Q4; Q4 net sales were $155.4 million, up 10.9% year-over-year.
  • +13 more takeaways
RYAM March 4, 2026

Rayonier Advanced Materials Q4 2025 Earnings Call - Deliver Positive Free Cash Flow in 2026

New CEO Scott Sutton laid out a surgical, urgent plan: fix the cash burn first, then lift value across cellulose specialties and every business line. RYAM reported negative free cash flow of $88 milli...

  • RYAM generated negative free cash flow of $88 million in 2025, and management calls the combination of cash burn plus high-cost debt unsustainable.
  • Top priority is clear and public: deliver positive free cash flow in 2026, with every group treating it as mission critical.
  • 85% of Cellulose Specialties volumes are now under contracts averaging an 18% price increase, but those deals carry an expected roughly 20% volume decline versus 2025.
  • +12 more takeaways
ANF March 4, 2026

Abercrombie & Fitch 4th Quarter Fiscal Year 2025 Earnings Call - Record FY25 Sales and Double-Digit Margins, but Tariffs and ERP Create Near-Term Headwinds

Abercrombie & Fitch closed fiscal 2025 with record revenue and robust profitability, proving the company can scale. Full-year net sales topped $5.27 billion, driven by broad-based growth at Hollister ...

  • Fiscal 2025 was a record year: net sales $5.27 billion, up about 6% year over year, the first time ANF surpassed $5 billion.
  • Q4 net sales were $1.67 billion, up 5% versus last year, with comparable sales roughly +1% and balanced growth across regions, brands, and channels.
  • Hollister was the growth engine: fiscal year net sales up 15% with comparable sales +13%, and Q4 marked the brand's 11th consecutive quarter of growth.
  • +12 more takeaways
NXE March 4, 2026

NexGen Energy Q4 2025 Earnings Call - Project Ready to Start Construction Pending Final Federal Approval and CAD 1.1B Cash

NexGen says it is poised to transition Rook One from development to construction once final federal approval arrives, after completing the two-part Canadian Nuclear Safety Commission hearings and rece...

  • CNSC process effectively complete, staff have recommended approval after two-part hearings, opening the path to final federal sign-off and construction consent.
  • NexGen finished 2025 with approximately CAD 1.1 billion in cash, after a CAD 950 million equity raise, providing runway for the first year of construction.
  • Management reiterates a CAD 2.2 billion total CapEx estimate for Rook One, stating no material movement despite inflationary pressure.
  • +11 more takeaways
WIX March 4, 2026

Wix Q4 2025 Earnings Call - Base44 hits ~$100M ARR as Harmony lifts cohorts and management doubles down with $2B buyback

Wix closed 2025 with solid growth and a headline breakout: Base44, acquired less than a year earlier, scaled to roughly $100 million of ARR, rapidly expanding Wix’s total addressable market from websi...

  • Base44 breakout: Base44 reached approximately $100 million of ARR within months of acquisition, positioning it among the fastest-growing software platforms in history.
  • Wix Harmony traction: Harmony, launched in English in January, is already improving new-cohort conversion, ARPU, and monetization, and management plans to make it the default experience over time.
  • Aggressive capital return: Wix expects to complete the large majority of its $2 billion repurchase program this year, citing conviction that the stock undervalues its long-term opportunity.
  • +16 more takeaways